Cyclerion's 400% Stock Surge Follows Shock Merger with Korsana Biosciences

Cyclerion Therapeutics has agreed to merge with Korsana Biosciences, sending its share price soaring by over 400% in a single day. The deal will create a new company, trading under the ticker 'KRSA' on the Nasdaq, with existing Cyclerion investors holding just 1.5% of the combined entity. The merger follows a strategic review by Cyclerion, which reported $2.07 million in revenue last year but also a net loss of $3.53 million. Legacy programs from Cyclerion are expected to be sidelined as the focus shifts to Korsana's pipeline, including its Alzheimer's candidate, KRSA-028. However, human efficacy data for this drug won't arrive until late 2027.

A private investment round led by Fairmount and Venrock Healthcare Capital Partners raised around $380 million. This funding is projected to support operations through 2029, giving the company a long runway for clinical development. Jonathan Violin, Korsana's current CEO, will lead the merged business, while Tomas Kiselak from Fairmount takes the chairman role. Korsana's stock history has been volatile. After its March 2024 IPO, shares jumped over 200% in the first week on strong immunotherapy trial results, only to fall 60% by mid-April due to market swings, insider sales, and FDA delays. By April 2026, the stock traded at roughly $12 per share.

The deal leaves Cyclerion's original shareholders with a small stake in the new company. Korsana's backers will control 98.5%, and the combined firm will now focus on advancing its drug pipeline. The merger's success will depend on future clinical results and regulatory progress.